Celldex Therapeutics, Inc. (CLDX) Spending and interest coverage
- R&D / revenue · 12 months: Value 176460.13%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 21924.68%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 176460.13% | Research and development expense / revenue. Period ending 2026-06-30. $278.81M ÷ $158.00K × 100 ≈ 176460.13% |
| Stock-based compensation / revenue · 12 months | 21924.68% | Share-based compensation / revenue. Period ending 2026-06-30. $34.64M ÷ $158.00K × 100 ≈ 21924.68% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 278.81M USD | Research and Development Expense |
| Revenue | 158.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 34.64M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -325.83M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $278.81M | $158.00K | $34.64M | $-325.83M | (m) | 176460.13% | 21924.68% | (m) | (m) |
| 2026-03-31 | $265.46M | $865.00K | $35.42M | $-309.06M | (m) | 30689.13% | 4095.26% | (m) | (m) |
| 2025-12-31 | $245.07M | $1.54M | $36.22M | $-287.37M | (m) | 15862.39% | 2344.14% | (m) | (m) |
| 2025-09-30 | $216.68M | $2.60M | $37.09M | $-256.24M | (m) | 8337.05% | 1427.01% | (m) | (m) |
| 2025-06-30 | $199.01M | $5.79M | $37.91M | $-234.75M | (m) | 3437.17% | 654.70% | (m) | (m) |
| 2025-03-31 | $184.50M | $7.56M | $36.36M | $-217.21M | (m) | 2440.84% | 480.96% | (m) | (m) |
| 2024-12-31 | $163.55M | $7.02M | $34.24M | $-195.08M | (m) | 2329.77% | 487.78% | (m) | (m) |
| 2024-09-30 | $147.04M | $9.98M | $31.67M | $-186.68M | (m) | 1473.91% | 317.50% | (m) | (m) |
| 2024-06-30 | $136.31M | $8.30M | $29.18M | $-175.79M | (m) | 1641.70% | 351.38% | (m) | (m) |
| 2024-03-31 | $122.87M | $6.07M | $26.75M | $-162.68M | (m) | 2023.62% | 440.58% | (m) | (m) |
| 2023-12-31 | $118.01M | $6.88M | $23.89M | $-154.54M | (m) | 1714.53% | 347.09% | (m) | (m) |
| 2023-09-30 | $110.48M | $4.37M | $21.19M | $-134.80M | (m) | 2531.13% | 485.36% | (m) | (m) |
| 2023-06-30 | $97.52M | $3.25M | $18.56M | $-121.26M | (m) | 2996.96% | 570.41% | (m) | (m) |
| 2023-03-31 | $92.00M | $3.15M | $16.80M | $-124.45M | (m) | 2920.63% | 533.27% | (m) | (m) |
| 2022-12-31 | $82.26M | $2.36M | $15.61M | $-115.23M | (m) | 3489.94% | 662.32% | (m) | (m) |
| 2022-09-30 | $74.04M | $1.08M | $14.24M | $-107.69M | (m) | 6868.00% | 1321.24% | (m) | (m) |
| 2022-06-30 | $66.02M | $823.00K | $12.78M | $-100.82M | (m) | 8021.99% | 1552.37% | (m) | (m) |
| 2022-03-31 | $57.65M | $4.14M | $10.83M | $-77.86M | (m) | 1392.44% | 261.62% | (m) | (m) |
| 2021-12-31 | $53.31M | $4.65M | $8.95M | $-71.24M | (m) | 1146.23% | 192.50% | (m) | (m) |
| 2021-09-30 | $49.06M | $8.10M | $7.07M | $-75.68M | (m) | 605.50% | 87.26% | (m) | (m) |
| 2021-06-30 | $46.21M | $8.62M | $5.29M | $-69.20M | (m) | 536.20% | 61.39% | (m) | (m) |
| 2021-03-31 | $43.56M | $5.38M | $4.50M | $-67.13M | (m) | 810.40% | 83.78% | (m) | (m) |
| 2020-12-31 | $42.53M | $7.42M | $3.92M | $-63.35M | (m) | 573.39% | 52.78% | (m) | (m) |
| 2020-09-30 | $42.45M | $4.52M | $3.35M | $-51.56M | (m) | 939.12% | 74.00% | (m) | (m) |
| 2020-06-30 | $42.84M | $4.40M | $2.80M | $-49.06M | (m) | 974.08% | 63.71% | (m) | (m) |
| 2020-03-31 | $43.22M | $4.88M | $3.54M | $-49.96M | (m) | 886.30% | 72.70% | (m) | (m) |
| 2019-12-31 | $42.67M | $3.57M | $4.55M | $-55.03M | (m) | 1194.29% | 127.37% | (m) | (m) |
| 2019-09-30 | $43.54M | $4.45M | $5.62M | $-54.16M | (m) | 978.43% | 126.20% | (m) | (m) |
| 2019-06-30 | $44.36M | $4.84M | $6.70M | $-50.09M | (m) | 915.73% | 138.36% | (m) | (m) |
| 2019-03-31 | $55.73M | $6.89M | $7.29M | $-54.70M | (m) | 808.19% | 105.67% | (m) | (m) |
| 2018-12-31 | $66.45M | $9.54M | $8.08M | $-156.44M | (m) | 696.68% | 84.72% | (m) | (m) |
| 2018-09-30 | $78.71M | $11.23M | $8.91M | $-169.84M | (m) | 700.85% | 79.37% | (m) | (m) |
| 2018-06-30 | $88.70M | $14.21M | $9.86M | $-194.03M | (m) | 624.05% | 69.36% | (m) | (m) |
| 2018-03-31 | $92.25M | (m) | $11.26M | $-206.09M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $96.17M | $12.74M | $12.31M | $-121.53M | (m) | 754.70% | 96.62% | (m) | (m) |
| 2017-09-30 | $97.27M | $11.16M | $13.34M | $-130.85M | (m) | 871.55% | 119.50% | (m) | (m) |
| 2017-06-30 | $100.36M | $9.46M | $14.39M | $-128.89M | (m) | 1061.22% | 152.19% | (m) | (m) |
| 2017-03-31 | $101.07M | $7.02M | $14.92M | $-132.32M | (m) | 1440.39% | 212.57% | (m) | (m) |
| 2016-12-31 | $102.73M | $6.79M | $15.32M | $-132.92M | (m) | 1513.79% | 225.71% | (m) | (m) |
| 2016-09-30 | $102.07M | $6.70M | $15.81M | $-131.50M | (m) | 1522.49% | 235.77% | (m) | (m) |
| 2016-06-30 | $101.71M | $5.51M | $15.88M | $-133.88M | (m) | 1846.66% | 288.29% | (m) | (m) |
| 2016-03-31 | $102.49M | $6.30M | $14.43M | $-134.26M | (m) | 1627.65% | 229.20% | (m) | (m) |
| 2015-12-31 | $100.17M | $5.48M | $12.77M | $-129.54M | (m) | 1827.94% | 233.10% | (m) | (m) |
| 2015-09-30 | $103.30M | $5.17M | $10.81M | $-128.15M | (m) | 1999.55% | 209.25% | (m) | (m) |
| 2015-06-30 | $104.83M | $5.24M | $8.90M | $-126.12M | (m) | 1999.75% | 169.76% | (m) | (m) |
| 2015-03-31 | $102.44M | $3.66M | $7.88M | $-121.92M | (m) | 2801.86% | 215.62% | (m) | (m) |
| 2014-12-31 | $104.38M | $3.59M | $6.85M | $-122.43M | (m) | 2910.79% | 191.08% | (m) | (m) |
| 2014-09-30 | $95.16M | $2.73M | $5.87M | $-112.49M | (m) | 3486.95% | 214.99% | (m) | (m) |
| 2014-06-30 | $89.39M | $2.61M | $5.92M | $-105.42M | (m) | 3427.53% | 227.19% | (m) | (m) |
| 2014-03-31 | $80.38M | $2.11M | $5.09M | $-95.53M | (m) | 3804.12% | 240.89% | (m) | (m) |
| 2013-12-31 | $67.40M | $4.11M | $4.55M | $-81.44M | $927.00K | 1639.53% | 110.63% | -87.86× | Reported |
| 2013-09-30 | $63.34M | $7.14M | $4.08M | $-75.88M | $1.19M | 887.43% | 57.21% | -63.60× | Reported |
| 2013-06-30 | $54.70M | $9.27M | $2.59M | $-67.36M | $1.56M | 589.98% | 27.98% | -43.15× | Reported |
| 2013-03-31 | $50.72M | $11.18M | $2.37M | $-62.19M | $1.45M | 453.54% | 21.15% | -42.80× | Reported |
| 2012-12-31 | $47.40M | $11.20M | $2.30M | $-58.08M | $1.58M | 423.12% | 20.51% | -36.85× | Reported |
| 2012-09-30 | $43.47M | $9.99M | $2.25M | $-53.91M | $1.66M | 435.22% | 22.55% | -32.42× | Reported |
| 2012-06-30 | $40.30M | $9.24M | $2.30M | $-50.64M | $1.72M | 436.18% | 24.86% | -29.44× | Reported |
| 2012-03-31 | $36.35M | $9.18M | $2.40M | $-47.03M | $1.74M | 395.94% | 26.17% | -26.97× | Reported |
| 2011-12-31 | $32.44M | $9.27M | $2.34M | $-43.40M | $1.80M | 350.12% | 25.28% | -24.16× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $27.65M | $46.79M | $2.80M | $-6.46M | $1.34M | 59.09% | 5.99% | -4.83× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $26.17M | $15.18M | $3.06M | $-36.85M | $452.00K | 172.39% | 20.14% | -81.53× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |